Skip to main
TWST

TWST Stock Forecast & Price Target

TWST Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Twist Bioscience is poised for potential growth and success with its unique silicon-based DNA synthesis platform and strong positioning in the growing field of AI-enabled drug discovery. The company has a proven track record of beating and raising quarterly estimates and is expected to continue this trend, with potential upside to FY26 revenue guidance. Its NGS segment is a core growth engine that is still underappreciated, while its margins are also expected to improve as the company moves towards profitability. Additionally, the company's focus on cost efficiency and capacity expansion position it well for future growth and profitability.

Bears say

Twist Bioscience is facing execution risk around margins and operating leverage due to its profitability story relying on continued gross margin improvement and disciplined expense control. The risks to the Medical and Life Science Tools sector also pose a challenge, as any reduction or delay in research and development budgets or government funding could impact Twist Bioscience's revenues. Additionally, while the company's recent financial results have been strong, there is a risk of a slowdown in its NGS momentum, potentially due to competition, customer concentration, or end-market variability.

TWST has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Twist Bioscience Corp (TWST) Forecast

Analysts have given TWST a Buy based on their latest research and market trends.

According to 9 analysts, TWST has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Twist Bioscience Corp (TWST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.